Abstract
Atopic dermatitis (AD) is a common skin disorder, characterized by impaired skin barrier function and cutaneous inflammation. The pathophysiology of AD is incompletely understood, and has considerable genetic contributions. To obtain a detailed molecular understanding of AD, we integrated the genomic, skin transcriptomic, and clinical measurements from 30 AD and 30 healthy control (HC) subjects. We found that the AD group had mild-to-moderate disease severity and only showed slightly increased genetic risk compared with HC. When comparing within the AD group, we found that the lesional skin of patients with increased genetic risk was characterized by a possible “self-protection” mechanism, including elevation of the anti-inflammatory cytokine IL-34, activation of fibroblasts, wound healing, and the complement system. We hypothesize that this mechanism may contribute to halting further progression of AD.
Competing Interest Statement
Ilka Hoof and Thomas Litman are LEO Pharma employees. Tu Hu and Joel Correa da Rosa were former employees of LEO Pharma. Lone Skov has been an adviser, investigator, and speaker for AbbVie, Eli Lilly, Novartis, Sanofi, Celgene, LEO Pharma, BMS, UCB, and BI, outside the submitted work. Lone Skov reports nonfinancial support from AbbVie, Sanofi, and Janssen and grants from Novartis, Janssen, BMS, and Sanofi. Tanja Todberg has been an investigator for Novartis, AbbVie, Dr Wolff, Galderma, and Almirall. This study was funded by LEO Pharma A/S.
Funding Statement
This study was funded by LEO Pharma (Ballerup, Denmark).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Danish Data Protection Agency (HGH-2029-002, i-suite6.999) and the ethical committee of the Capital Region of Denmark (H-17015302) and was conducted in accordance with the Declaration of Helsinki. All participants gave their written, informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
RNA sequencing data are available in Gene Expression Omnibus under the accession GSE193309. Genetic risk score is available in the supplementary table.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE193309
